Michael Klein
Chairman & CofounderArcana CollectiveMichael Klein is Chairman & Cofounder of Arcana Collective, a first-of-its-kind collaboration uniting the most respected OG cannabis breeders who hold the IP to a variety of iconic foundational strains and possess profound wisdom of the plant’s genetics and science. By cross- breeding these strains with a diverse array of popular cultivars, Arcana is developing a robust library of F1 hybrids, paving the way for future releases of unique cannabis genetics.
Klein is an impactful entrepreneur who has repeatedly built and successfully exited businesses across a wide range of sectors, from technology and mining to music/hospitality and reservoir development. His commitment extends beyond business; as an ardent environmentalist and philanthropist, he has dedicated over 35 years to serving on environmental and children’s advocacy boards. Currently, he is co-founder and Chairman of bio365, where he continues to innovate by providing premium organic living soils to the controlled environment agriculture sector, including Cannabis.
Genetics as Strategy: Continuous Optimization for Commercial Cannabis Cultivation
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space, and competitive position.
This session shows commercial growers how to flip that script. You'll learn how leading operators replace reactive trend-chasing with a structured genetic program built
The cannabis market moves faster than your cultivation cycles. By the time a trend hits the shelf, most teams are still six months behind, scrambling to source, trial, and scale genetics that buyers already expect. That lag costs margin, shelf space, and competitive position.
This session shows commercial growers how to flip that script. You'll learn how leading operators replace reactive trend-chasing with a structured genetic program built on continuous sourcing, trialing, and evaluation. We'll connect each decision to commercial viability, so genetics become a strategic asset rather than a guessing game.
